SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is seeing intense community speculation as investors debate whether the asset is primed for a massive short squeeze or experiencing a cycle of recurring pump-and-dump activity. Traders are actively tracking volume spikes and social sentiment while closely monitoring technical levels for signs of a potential sustained breakout.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Churchill Capital Corp XI - Ordinary Shares - Class A

Churchill Capital Corp XI is attracting significant interest due to its pending merger with Agility Robotics, a move that has sparked intense debate over whether it represents a transformative investment or a classic SPAC pump-and-dump scheme. While proponents highlight the company's high-profile backing from heavyweights like Amazon and Nvidia, skeptics are questioning the lack of tangible industrial sales and the inherent risks associated with the post-merger valuation model.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin (XCN) is currently trending as investors focus on the upcoming launch of the Goliath mainnet, with the community actively debating whether the rollout will serve as a major catalyst for long-term institutional adoption or result in another "sell the news" price drop. While some investors are aggressively accumulating and highlighting the protocol's high-speed, compliant infrastructure, skeptics remain vocal, labeling the project a liquidity-focused scheme and warning others about historical volatility and lack of transparent partnerships.

Oatly Group AB is a holding company, which focuses on developing expertise around oats, a global power crop with inherent properties suited for sustainability and human health. It operates through the following geographical segments: Europe & International, North America and Greater China. The company was founded by Björn Öste in 1994 and is headquartered in Malmö, Sweden.

Oatly Group AB - ADR

Oatly Group

Oatly is currently a major focus for investors as the community eagerly awaits a potential China carve-out to stabilize the balance sheet and bolster liquidity. Despite concerns over debt and share price performance, there is significant enthusiasm surrounding the company's expansion into new product categories like matcha and cold foam, which many hope will drive the next wave of profitable growth.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol-Myers Squibb is trending as investors show renewed interest following positive clinical updates for its oncology and cardiovascular pipeline, including trial results for Camzyos and label expansions for Breyanzi. The community is actively discussing the stock's potential for a long-term turnaround, focusing on its ability to mitigate future patent cliffs through strategic R&D investments and steady dividend payouts.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as the community debates the project's long-term viability following a leadership transition and persistent downward price action. While some investors remain committed to the long-term utility of Flexa's payment rails and potential regulatory milestones, others are vocal about their frustration regarding lack of communication and significant portfolio losses.

DigitalOcean Holdings, Inc. engages in the provision of providing cloud infrastructure. It operates through the following geographical segments: United States, Netherlands, Germany, Canada, Singapore, and Other. The company was founded in 2012 and is headquartered in Broomfield, CO.

DigitalOcean Holdings Inc

DigitalOcean is trending as investors aggressively rotate into the physical AI infrastructure layer, fueled by a narrative shift toward cloud-based agentic AI and robust revenue growth. The community is actively debating the company's valuation relative to its pivot toward high-margin AI inference workloads and its capacity to sustain momentum heading into earnings.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as investors actively accumulate tokens amidst high staking participation and anticipation of institutional payroll adoption. The community remains focused on key catalysts like the Clarity Act and the expansion of the SuperApp, viewing recent market dips as strategic entry points for long-term positioning.

Re is an internet-native marketplace for insurance capital. It connects eligible capital providers with fully collateralized reinsurance activity conducted through licensed insurance entities. Blockchain infrastructure makes collateral, reserves, and selected operating data verifiable onchain. RE is the governance token of the Re Protocol. It governs protocol upgrades, technical permissions, committee formation, reporting standards, incentive policy, and governance procedures. Underwriting, claims, pricing, reserve decisions, and regulated operations remain with qualified professionals and licensed entities.

Investors are actively debating the potential of RE following recent listings on major exchanges and community excitement surrounding its utility within the decentralized reinsurance market. While some participants are closely monitoring support levels and technical chart patterns, others are focused on the project's long-term institutional backing and RWA narrative.

Air Canada engages in the provision of airline transportation services. Its services cover full-service airline, scheduled passenger and cargo services, serving more than two hundred airports on six continents. It operates through the following geographical segments: Canada, U.S. Transborder, Atlantic, Pacific, and Other. The company was founded on April 11, 1936 and is headquartered in Saint-Laurent, Canada.

Air Canada Inc. - Ordinary Shares (Voting and Variable Voting)

Air Canada Inc.

Air Canada is experiencing heightened investor interest as the community weighs strong international passenger demand and capacity optimization against volatility in jet fuel costs and geopolitical tensions. Market sentiment remains divided between bulls focused on margin expansion and long-term recovery, and critics concerned by the stocks historical underperformance compared to sector peers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

J&J Stock Down 3% in 3 Months: Is the Dip a Buying Opportunity?

J&J's shares fall 3% in three months despite solid results and pipeline progress, raising questions about whether the pullback is a buying opportunity.

JNJ and AZN Face Patent Headwinds: Which Stock Looks Stronger Now?

J&J's diversified healthcare business and growth outlook help it stand out against AstraZeneca despite patent and legal challenges.

J&J Stock Gains Nearly 12% Year to Date: Buy, Sell or Hold Now?

JNJ is up nearly 12% YTD as strong oncology drug growth, MedTech demand and pipeline advances help offset Stelara patent-loss pressure.

J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?

JNJ's diversified pharma and MedTech growth, pipeline progress and stronger 2026 outlook give it an edge over PFE.

J&J's Pipeline Progress & New Drugs Promise Stronger Long-Term Growth 

J&J's expanding pipeline, new drug approvals and rising sales from cancer medicines are expected to fuel growth.

Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy

JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure.

Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Expected to Rise, Wedbush Analyst Says

Wedbush upped their target price on shares of Protagonist Therapeutics from $112.00 to $118.00 and gave the stock an 'outperform' rating in a research report on Wednesday...

Protagonist Therapeutics (NASDAQ:PTGX) Posts Earnings Results, Beats Expectations By $0.70 EPS

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported $0.05 earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.70. The company had revenue of $56.37 million for the quarter, compared to...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Moderate Buy" from Analysts

Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) has received an average recommendation of "Moderate Buy" from the fifteen ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a ho...

331,164 Shares in Protagonist Therapeutics, Inc. $PTGX Bought by Jennison Associates LLC

Jennison Associates LLC bought a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 331,164 shares of the company's stock, v...

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Protagonist Therapeutics Inc

Wall Street Says Johnson And Johnson’s FDA-Approved Psoriasis Drug Should Create 'Significant Value’ For Protagonist Therapeutics

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$121.88
Prev Close	$122.63
Open	$122.00
Dividend Yield	0.00%
50-Day Moving Average	$103.77
Beta	0.55
Avg. Volume	519,070.92
PE Ratio	-67.98

52-Week High	$126.25
52-Week Low	$49.38
Market Capitalization	$7.84B
EPS (Annual)	-$2.05
Price to Book	12.02
Revenue Per Employee	$348,606.06

Feed

News

Sentiment

Earnings

Fundamentals

Info

PTGXProtagonist Therapeutics Inc

Latest PTGX News